Alnylam metabolic, hematology news

Alnylam launched its "Alnylam 5x15" strategy with the goal of moving five RNAi therapeutic programs into advanced clinical development by 2015. The most advanced of the five programs is ALN-TTR, which consists of ALN-TTR01 and ALN-TTR02, both of which are RNAi therapeutics against the transthyretin (TTR) gene in development for TTR-mediated amyloidosis. ALN-TTR01 is in Phase I testing, while ALN-TTR02 is expected to begin Phase I testing in 2H11. ...